Mankind Pharma reported its Q3 FY26 financial results through an earnings call held on February 3, 2026, showing revenue growth amid ongoing organizational transformation challenges that have impacted overall performance.

Consolidated Financial Performance

The company delivered consolidated revenue from operations of ₹35.67 billion for Q3 FY26, representing an 11.5% year-on-year increase from ₹31.99 billion in Q3 FY25. For the nine-month period, revenue reached ₹108.35 billion, marking an 18.7% year-on-year growth.

Consolidated net profit reached ₹4.14 billion compared to ₹3.78 billion in the year-ago quarter, showing a 9.5% improvement. The diluted EPS stood at ₹9.90 per share, while Cash EPS increased to ₹15.60 from ₹13.90, marking a 12.1% year-on-year growth.

Business Segment Performance

Domestic business recorded revenue of ₹30.46 billion in Q3 FY26, representing 11.1% year-on-year growth with organic growth of 9.1% excluding OTC. The company's chronic therapy segment continued strong performance with cardio growing 16.7% and antidiabetes expanding 14.4% in Q3.

The company's chronic therapy contribution increased by 200 basis points year-on-year to 36.7% in the nine-month period, outperforming IPM by 1.2x in cardio and 2.2x in antidiabetic segments excluding GLP-1.

Transformation Challenges and Recovery

Management acknowledged significant organizational transformation challenges over the past 12-15 months, including field force restructuring that impacted approximately 20-25% of the team. Vice Chairman Rajeev Juneja explained that the company underestimated the complexity of integrating new personnel with Mankind's unique culture focused on daily sales hygiene rather than traditional targets.

The acute therapy segment, representing approximately 60% of business, was particularly affected due to its dependence on personal relationships with general practitioners. However, management expressed confidence in gradual recovery with improving team stability and reduced attrition rates.

Profitability and Margin Analysis

Gross margins improved by 170 basis points year-on-year to 72.6% in Q3 FY26, driven by sales price increases, favorable sales mix, and inventory-related accrual releases. However, adjusted EBITDA margin declined to 25.9% from 27.6% due to increased R&D costs and higher employee expenses.

The company maintained its R&D guidance of 2.5-3% of revenue and capex guidance of 4-5% of revenue, with nine-month capex spending at ₹4.73 billion representing 4.4% of total revenue.

Mankind Pharma has announced its quarterly investor conference call to discuss Q3 and 9M FY26 financial results. The pharmaceutical company informed stock exchanges about the scheduled earnings call on January 16, 2026, in compliance with SEBI regulations.

Earnings Call Schedule

The investor conference call is scheduled for February 3, 2026, and will run for one hour from 6:00 PM to 7:00 PM IST. The call aims to provide insights into the company's business performance and financial results for the third quarter and nine-month period of FY26.

Dial-in Information

The company has provided comprehensive access options for investors and analysts to participate in the earnings call. Multiple dial-in numbers are available to accommodate both domestic and international participants.

Participants can pre-register for the call to avoid wait times and dial in directly without waiting for operator assistance.

Management Participation

The earnings call will feature comprehensive representation from Mankind Pharma's senior leadership team. Seven key executives will participate to provide detailed insights into the company's performance and address investor queries.

Senior Management Participants:

• Mr. Rajeev Juneja – Vice Chairman & Managing Director
• Mr. Sheetal Arora – Chief Executive Officer & Whole Time Director
• Mr. Arjun Juneja - Chief Operating Officer
• Mr. Sudipta Roy – Senior President – Sales & Marketing
• Mr. Ashutosh Dhawan – Global Chief Financial Officer
• Mr. Prakash Agarwal – President (Strategy)
• Mr. Abhishek Agarwal – Head - Investor Relations & AVP - Strategy

Contact Information

For additional details regarding the earnings call, investors can reach out through multiple channels. The company has provided both internal and external contact points for investor relations support.

The announcement was formally communicated to BSE Limited and National Stock Exchange of India Limited under Regulation 30 and 51 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary & Compliance Officer Hitesh Kumar Jain signed the regulatory filing, and the details are also available on the company's official website at www.mankindpharma.com .